About Course
Gastro-oesophageal reflux disease (GERD) is a chronic, relapsing condition, with a prevalence of 10-20% of the population. Over the decades, Proton pump inhibitors have remained the back- bone in the management of GERD. However, several areas of unmet need persist in the management of advanced grades of erosive esophagitis, refractory GERD, and it’s rapidly progressing towards adenocarcinoma. In this CME, We focus on some promising insights of recent advances in interventional endoluminal...




